Akèy › Kansè lestomak › New York › New York City
Etid klinik pou Kansè lestomak nan New York City, NY
31 etid pou Kansè lestomak ap chèche patisipan nan sit nan ak bò kote New York City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 2
- Memorial Sloan Kettering Hospital, New York
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Ap rekriteFaz 2/3
- Memorial Sloan Kettering Cancer Center, New York
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
Ap rekriteFaz 3
- Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Ap rekriteFaz 2/3
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
- Rockefeller Outpatient Pavilion (53rd Street), New York
- Memorial Sloan Kettering Cancer Center - Main Campus, New York
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
Ap rekriteFaz 2
- Research Site, New York
A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer
Ap rekriteFaz 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Ap rekriteFaz 1
- New York University (NYU) Langone Medical Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Ap rekriteFaz 1
- New York University (NYU) Clinical Cancer Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- Columbia University, New York
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
Ap rekriteFaz 3
- Icahn School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma
Ap rekriteFaz 1/2
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Ap rekriteFaz 1
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Ap rekriteFaz 3
- Research Site, New York
- Research Site, New York
- Research Site, New York
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Ap rekriteFaz 1
- Icahn School of Medicine at Mount Sinai, New York
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Ap rekriteFaz 1/2
- Memorial Sloan Kettering Hospital, New York
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Ap rekriteFaz 1
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Ap rekriteFaz 3
- Memorial Sloan Kettering Cancer Center - MAIN, New York
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Mt. Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
- Icahn School of Medicine at Mount Sinai, New York
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Ap rekriteFaz 2
- Memorial Sloan Kettering Cancer Center, New York
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Ap rekriteFaz 1
- North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists, New York
- Columbia University Irving Medical Center, New York
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Ap rekriteFaz 1
- New York Medicine-New York-Presbyterian Hospital, New York
- Montefiore Medical Center - Montefiore Hospital, New York
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Ap rekriteFaz 2
- Research Site, New York
Brodalumab in the Treatment of Immune-Related Adverse Events
Ap rekriteFaz 1
- Columbia University Irving Medical Center, New York
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- NYU Langone, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study Collecting Health Information to Understand and Prevent Gastric Cancer
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Memorial Sloan Kettering Cancer Center (All protocol activites), New York
Avutometinib and Defactinib in Diffuse Gastric Cancer
Ap rekriteFaz 2
- Columbia University Irving Medical Center, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, New York
Comprehensive Outcomes for After Cancer Health
Ap rekriteVolontè an sante akeyi
- Memorial Sloan Kettering Cancer Center, New York
Etid Kansè lestomak nan lòt vil
- Houston, TX42 etid
- Boston, MA32 etid
- Nashville, TN28 etid
- Baldwin Park, CA22 etid
- Los Angeles, CA22 etid
- Arlington, VA20 etid
- Dallas, TX19 etid
- San Antonio, TX19 etid
- Grand Rapids, MI18 etid
- St. Louis, MO18 etid
- Washington, DC16 etid
- Chicago, IL16 etid
Lòt etid nan New York City
- Kansè nan tete136 etid
- Kansè Poumon ki pa ti selil121 etid
- Kansè (tout kalite)109 etid
- Kansè pwostat103 etid
- Kansè Metastatik93 etid
- Kansè kolorektal78 etid
- Kansè ovè69 etid
- Kansè poumon60 etid
- Myelom Miltip60 etid
- Kansè pankreyas60 etid
- Kansè Endomèt52 etid
- Leksemi mieloïd egi51 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.